Form 4: Precigen Inc. COO Rutul R. Shah Acquires 550,000 Stock Options

Rutul R. Shah, Chief Operating Officer of Precigen, Inc., reports the acquisition of 550,000 stock options on May 31, 2024.

Summary

• On May 31, 2024, Rutul R. Shah, the Chief Operating Officer of Precigen, Inc. (PGEN), acquired 550,000 options to purchase common stock.
• The exercise price of these options is $1.40.
• The options vest 25% on May 31, 2025, and the remainder vest in equal monthly installments over the following three years.
• The expiration date for these options is May 31, 2034.
• Following this transaction, Shah directly owns 550,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing indicating an executive's stock option grant. While option grants can be seen as a positive incentive, the filing itself doesn't convey strong positive or negative sentiment.

Positives

• The acquisition of stock options by a key executive like the COO can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure related to executive compensation and is common in the biotechnology industry.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry, used to align management's interests with those of shareholders.
• The vesting schedule of 25% after one year followed by monthly installments is a typical arrangement.
• Comparing the size of the grant to those of peer companies would require further analysis of Precigen's compensation policies and market capitalization.

Stakeholder Impact

• Shareholders may view the option grant as an incentive for the COO to drive company performance.
• Employees may see this as a positive sign of management's commitment to the company.

Key Dates